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Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the 
central nervous system. It was previously shown that toll-like receptor (TLR)-2 signaling 
plays a key role in the murine experimental autoimmune encephalomyelitis (EAE) model 
of MS, and that TLR2-stimulation of regulatory T cells (Tregs) promotes their conversion 
to T helper 17 (Th17) cells. Here, we sought potential sources of TLR2 stimulation and 
evidence of TLR2 activity in MS patient clinical samples. Soluble TLR2 (sTLR2) was 
found to be significantly elevated in sera of MS patients (n = 21), in both relapse and 
remission, compared to healthy controls (HC) (n = 24). This was not associated with the 
acute phase reaction (APR) as measured by serum C-reactive protein (CRP) level, which 
was similarly increased in MS patients compared to controls. An independent validation 
cohort from a different ethnic background showed a similar upward trend in mean sTLR2 
values in relapsing-remitting MS (RRMS) patients, and significant differences in sTLR2 
values between patients and HC were preserved when the data from the two cohorts 
were pooled together (n = 41 RRMS and 44 HC, P = 0.0006). TLR2-stimulants, mea-
sured using a human embryonic kidney (HEK)-293 cells transfectant reporter assay, were 
significantly higher in urine of MS patients than HC. A screen of several common urinary 
tract infections (UTI)-related organisms showed strong induction of TLR2-signaling in the 
same assay. Taken together, these results indicate that two different markers of TLR2-
activity—urinary TLR2-stimulants and serum sTLR2 levels—are significantly elevated in 
MS patients compared to HC.
Keywords: toll-like receptor 2, soluble Tlr2, multiple sclerosis, urinary tract infection, biomarker
Abbreviations: MS, multiple sclerosis; TLR, toll-like receptor; EAE, experimental autoimmune encephalomyelitis; Tregs, 
regulatory T cells; Th17, T helper 17 cells; sTLR2, soluble TLR2; APR, acute phase reaction; CRP, C-reactive protein; HEK, 
human embryonic kidney; UTI, urinary tract infections; CNS, central nervous system; RRMS, relapsing-remitting MS; 
PAMPs, pathogen-associated molecular patterns; DAMPs, danger associated molecular patterns; HC, healthy controls; DMTs, 
disease-modifying treatments; ELISA, enzyme-linked immunosorbent assay; CD, cluster of differentiation; NF-κB, nuclear 
factor kappa-light-chain-enhancer of activated B cells; BLP, bacterial lipopeptide equivalent equivalent; HP, Helicobacter pylori; 
PBS, phosphate-buffered saline; PBMC, peripheral blood mononuclear cells; PMA, phorbol 12-myristate 13-acetate; IL-1β, 
interleukin-1β; HepG2, hepatocarcinoma cell line.
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inTrODUcTiOn
Multiple sclerosis (MS) is a chronic immune-mediated inflam-
matory disease of the central nervous system (CNS) in which 
autoreactive lymphocytes infiltrate the blood–brain barrier to 
target axonal myelin damage leading to neurological complica-
tions (1). MS can have diverse forms of clinical course; the most 
common form at presentation is the relapsing-remitting (RR) 
MS, manifesting as recurrent attacks (relapses) of neurological 
dysfunction followed by periods of remission. T cells are known 
to play a central role in the pathogenesis of both MS and its animal 
model experimental autoimmune encephalomyelitis (EAE) and, 
therefore, T  cells remain the prime target of effective immu-
nomodulatory and immunosuppressive treatments in MS (2, 3).
Toll-like receptors (TLRs) are a family of innate immune 
receptors that serve to trigger inflammatory signaling through 
their detection of exogenous pathogen-associated molecular 
patterns (PAMPs) and endogenous danger associated molecular 
patterns. TLRs are known to play critical roles in both MS and 
EAE by influencing the initiation of the disease, the triggering of 
relapses, and regulation of CNS damage (4). TLR2 is reported to 
be expressed on many different cell types of the innate and adap-
tive immune systems, and also in the CNS (5, 6). Due to its ability 
to form heterodimers with either TLR1 or TLR6, TLR2 can sense 
a broad spectrum of microbial as well as endogenous ligands indi-
cating its importance both in infection and autoimmunity (7–9).
Although the etiology of MS is complex, both genetics and 
environmental factors are known to contribute to risk of disease 
(10). Infections are well recognized environmental triggers for 
MS susceptibility, pathogenesis, and exacerbation (11–13). For 
example, upper respiratory tract and urinary tract infections 
(UTI) are considered to be important triggers for the activation of 
inflammatory relapse in MS (14, 15). However, it remains unclear 
how bacterial infections may trigger exacerbations.
Previous results from our lab have shown that TLR2 stimula-
tion of human regulatory T cells (Tregs), which have impaired 
suppressive function in MS patients (16, 17), leads to reduced 
Treg function and drives their differentiation toward an inflam-
matory Th17-like phenotype (18). Moreover, Tregs from RRMS 
patients were more susceptible to such TLR2-induced effects 
compared to healthy controls (HC) (19). Thus, we hypothesized 
that exposure to stimulants of TLR2-signaling in vivo could shift 
the Treg/Th17 balance toward a proinflammatory state in MS, 
promoting disease activity and progression.
One of the major negative regulators of TLR-signaling is the 
generation of extracellular soluble TLRs, which serve as decoy 
receptors to limit ligand-induced signaling (20). In the human 
immune system, the soluble TLR2 (sTLR2) is reported to sup-
press TLR2-mediated inflammation, in part by preventing its 
binding to the co-receptor CD14 (21–23). sTLR2 may be pro-
duced by protease cleavage, or by ectodomain shedding (24, 25), 
resulting in at least six distinct sTLR2 polypeptides, which have 
been identified in human breast milk, plasma, and monocyte 
culture supernatant (23). Very recent data show that the cysteine 
protease calpain, which is released by activated T  cells, gener-
ates sTLR2 by cleavage of surface TLR2 in its transmembrane 
domain (26). sTLR2 can also be released from cells in response 
to TLR2-stimulation, suggesting that it could serve as a marker of 
recent TLR2-signaling, or other inflammatory activity (25).
In this study, we sought evidence of recent exposure to TLR2-
stimulation in MS patient clinical samples. sTLR2 levels were 
found to be significantly higher in sera of MS patients compared 
to HC, and TLR2-stimulants were present at significantly higher 
levels in urine of MS patients compared to HC, consistent with 
robust TLR2-activation by a panel of common UTI-relevant 
organisms. These results offer the first evidence that MS patients 
may be at risk of increased exposure to TLR2-ligands compared 
to healthy subjects.
MaTerials anD MeThODs
ethics statement
This study was carried out in accordance with the recommenda-
tions of Nottingham Research. Ethics Committee 2 with written 
informed consent from all subjects. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
The protocol was approved by the Nottingham Research Ethics 
Committee 2 (REC Reference 08/H0408/167).
study Participants
Multiple sclerosis patients attending outpatient clinics at Notting-
ham University Hospitals were recruited for this study. The study 
included 35 adult MS patients with clinically definite MS, accord-
ing to the McDonald Criteria (27), aged 17–57  years (mean: 
40.45 ± 10.6). 18 patients had not been treated with any disease-
modifying treatments (DMTs), 6 were taking interferon-β, 4 were 
on Glatiramer acetate, 3 were on Fingolimod, 2 were receiving 
Dimethyl fumarate, and 2 were receiving corticosteroids. In 
addition, 25 HC aged 26–58  years (mean: 40.73 ±  10.2) were 
recruited. A relapse was defined as patient-reported symptoms 
or objectively observed signs typical of an acute inflammatory 
demyelinating event in the CNS, lasting at least 24 h (27). HC 
had no history of autoimmune disease or recent symptomatic 
infections. There was no significant age difference between MS 
patients and HC (P = 0.153). All MS patients and HC gave written 
informed consent prior to blood and urine sampling. The study 
was approved by the Nottingham Research Ethics Committee 
and by Nottingham University Hospitals National Health Service 
Trust Research and Innovation Services. Age and sex-matched 
samples for the validation cohort were received from Univer-
sity Hospital San Luigi Gonzaga, Orbassano, Turin, Italy which 
included 20 adult RRMS patients aged between 21 and 55 years 
(mean 33.35 ± 10.74) and 20 HC aged between 22 and 57 years 
(mean 33.6 ± 10.97). All the samples in the validation cohort were 
treatment naïve and there was no age difference between RRMS 
and HC (P = 0.942). Both patients and controls were Caucasians, 
mainly from the Piedmont region. Demographic data for the two 
cohorts are presented in Table 1.
enzyme-linked immunosorbent  
assay (elisa)
Soluble TLR2 and sTLR4 were measured in serum and urine 
samples by ELISA (DTLR20, R&D Systems, UK, and SEA753Hu; 
TaBle 1 | Baseline demographics and clinical data of patients and HC.
Discovery cohort Validation cohort
Ms (n = 35) hc (n = 25) Ms (n = 20) hc (n = 20)
Age (mean ± SD) 40.45 ± 10.6 40.73 ± 10.2 33.35 ± 10.74 33.6 ± 10.97
Age range 17–57 26–58 21–55 22–57
P value 0.153 (ns) 0.942 (ns)
Male 11 11 5 5
Female 24 14 15 15
MS course RRMS (n = 35) – RRMS (n = 20) –
Disease duration in year from CIS (mean ± SEM) 8.79 ± 1.3 – 4.18 ± 1.85 –
Disease duration in year from CD-MS (mean ± SEM) 5.99 ± 0.99 – 0.36 ± 0.16 –
EDSS (mean ± SEM) N/A – 0.97 ± 0.21 –
ns, not significant; RRMS, relapsing-remitting MS, CIS, clinically isolated syndrome; CD-MS, clinically definite MS; EDSS; expanded disability status score; N/A, not available.
Disease duration was calculated from the CIS or CDMS date to the sampling date. EDSS in the discovery cohort were only available for 4 patients. EDSS in the validation cohort 
were available for 19 out of 20 patients.
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Cloud-Clone Corp., USA, respectively). For the validation cohort 
sTLR2 was measured using a different ELISA kit (SEA753Hu; 
Cloud-Clone Corp., USA). CRP was measured in serum samples 
by high-sensitivity ELISA (DY1707, R&D Systems).
Determination of Tlr2 stimulants
TLR2 stimulants in urine and serum samples from MS patients 
and HC were measured using a human embryonic kidney 
(HEK)-293 cell TLR-transfection assay, as described previ-
ously (28). Briefly, cells were transiently transfected with TLR2, 
CD14, nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB)-reporter, and thymidine-kinase promoter-driven 
reporter constructs, then challenged 3 days later with indicated 
concentrations of defined TLR-ligands, volunteer serums, heat-
killed urine samples, or heat-killed bacteria. 18 h later, NF-κB-
dependent reporter expression was measured by luminometry 
and normalized to co-transfected renilla reporter. A standard 
curve was prepared on each plate by plotting fold NF-κB induc-
tion vs concentration using the defined TLR2-ligand Pam3CSK4. 
Because it has been proposed that diverse ligands beyond lipo-
peptides may stimulate TLR2, the TLR2-stimulating capacity of 
the samples are presented as biological activities relative to this 
standard curve and are expressed as ng/ml Pam3CSK4-equivalents 
or bacterial lipopeptide equivalent (BLP) equivalents.
Tlr2 stimulating activity in heat-Killed 
Bacteria and Helicobacter pylori lysate
A selection of eight representative UTI-related Gram-positive 
and Gram-negative bacteria was tested using the same HEK-
293-TLR2 transfection system to determine their capacity 
to stimulate TLR2. All bacteria examined were of hazard 
group 2 or lower and were studied in a class 2 containment 
facility. A whole bacterial cell lysate was also prepared from 
H. pylori (SS1 strain) for assay in the same system. To prepare the 
lysate, H. pylori cultures from 10 blood agar base 2 plates (Oxoid) 
cultured for 24  h under microaerobic conditions at 37°C were 
harvested into ice-cold sterile phosphate-buffered saline. This 
suspension was then disrupted using a Soniprep 150 sonicator 
(SANYO, Watford, UK), with 6 × 10s bursts at amplitude of 10 µm, 
then aliquoted and stored at −20°C. There were approximately 
6  ×  109 bacteria per ml before sonication, corresponding to 
1 × 107 bacteria per ml when diluted, and the protein content of 
the lysate was 13.8 mg/ml as determined using the BCA protein 
assay kit (Thermo). The TLR2-stimulating capacities of bacteria 
and lysates in these experiments are presented as NF-κB fold 
induction vs cells cultured in medium alone.
Dipstick Test
Urine samples were tested using Combur-Test Strip dipsticks 
(Cobas, Roche, Switzerland). Positive results for leukocytes, 
nitrite, protein, and erythrocytes were considered potential signs 
of infection.
Flow cytometry
Flow cytometric analyses were carried out using frozen periph-
eral blood mononuclear cells (PBMC) from RRMS patients 
collected during relapse and remission. After thawing, the cells 
were cultured for 5  h (short-term stimulation) with phorbol 
12-myristate 13-acetate (0.1  µg/ml), ionomycin (1  µg/ml), and 
Brefeldin-A (10 µg/ml, added only in the last hour). After stimu-
lation and washing, cells were stained with Live/Dead® Fixable 
Blue Dead Cell Stain Kit (ThermoFisher Scientific) for 30 min at 
room temperature. Cells were then stained extracellularly with 
anti-CD4 (BD Pharmingen) and anti-TLR2 (eBioscience, Clone 
TL2.1). Cells were acquired using an LSR II flow cytometer (BD 
Biosciences), collecting a minimum of 50,000 events in each 
sample, and analyzed using Kaluza software (Beckman Coulter, 
version 1.5). Gating strategy ungated PBMCs were plotted on 
SSC/FSC plot and then lymphocytes were gated by excluding 
dead cells/debris. Then, from the lymphocytes, live cells were 
gated. Then, the percentage of live lymphocytes that were CD4+/
TLR2+ were selected.
calpain Treatment
Peripheral blood mononuclear cells from healthy volunteers 
were treated with 4 µg/ml of Calpain (Natural human Calpain 1 
protein, AbCam, Product no. ab91019) for 1 h at 37°C and then 
stained with anti-CD4 and anti-TLR2 antibodies and analyzed by 
flow cytometry as above. Gating strategy ungated PBMCs were 
plotted on SSC/FSC plot and then lymphocytes were gated by 
FigUre 1 | Level of soluble TLR2 (sTLR2), sTLR4, and hsC-reactive protein (CRP) measured by enzyme-linked immunosorbent assay in the sera of relapsing-
remitting (RR) MS (RRMS) patients and compared with HC. The data are presented as mean ± SD. (a) sTLR2 measured in the serum samples from RRMS patients 
during relapse (n = 21) and compared with HC (n = 24). Mann–Whitney test showed significantly higher sTLR2 values during relapse (P < 0.0001). Significantly 
higher sTLR2 values were also observed during remission (n = 21) compared to HC (P = 0.0002) (not shown). (B) Wilcoxon matched-pairs signed rank test 
between paired relapse and remission samples showed no significant difference (n = 14, P = 0.9032). (c) sTLR4 measured in the serum samples from RRMS 
patients during relapse (n = 14) and compared with HC (n = 18). Mann–Whitney test showed no significant differences (P = 0.9926). Comparison between 
remission (14) and HC also showed no significant difference (P = 0.0860) (not shown). (D) Wilcoxon matched-pairs signed rank test between paired relapse and 
remission samples showed no significant difference (n = 14, P > 0.9999). (e) Serum CRP measured in the samples from RRMS patients during relapse (n = 20) and 
HC (n = 14). Mann–Whitney test showed significantly higher CRP during relapse (P = 0.0352) compared to HC. No significant difference observed between HC vs 
remission samples (not shown). (F) Wilcoxon matched-pairs signed rank test between paired relapse and remission samples showed no significant difference 
(n = 14, P = 0.4263). * P < 0.05, **** P < 0.0001, ns, not significant.
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excluding dead cells/debris. Then, from the lymphocytes, CD4+ 
cells were gated and then percentage of TLR2+ cells from CD4+ 
population were identified.
statistical analyses
The data are presented as mean (±SD or SEM). All statistical 
analyses were performed using Prism 7.01 (GraphPad Software, 
San Diego, CA, USA). Data which were not normally distributed 
were log transformed before comparison of groups using the 
Mann–Whitney U test and Wilcoxon matched-pairs signed 
rank test (for paired samples). p Values <0.05 were considered 
significant.
resUlTs
levels of sTlr2 and c-reactive Protein 
(crP) are significantly elevated in sera  
of rrMs Patients
As it has been reported that serum sTLR2 is a biomarker of recent 
infection, and of disease activity in other conditions, we meas-
ured sTLR2 levels in serum samples from MS patients in relapse 
and remission and compared them with those from HC (29, 30). 
We observed significantly higher levels of sTLR2 in the serum 
samples of MS patients both during relapse (0.87  ng/ml) and 
remission (0.85  ng/ml) when compared with HC (0.58  ng/ml) 
(Figure 1A). However, there was no significant difference in the 
sTLR2 values between paired MS relapse and remission samples 
(n = 14, Figure 1B). Since, both TLR2 and TLR4 expression has 
been reported to be elevated in the PBMCs from MS patients and 
soluble forms for both of these receptors (sTLR2 and sTLR4) were 
detected in various infectious and non-infectious inflammatory 
conditions, we also measured sTLR4 levels in the serum samples 
(31, 32). We found that sTLR4 levels were not significantly dif-
ferent between groups (1.52, 2.14, and 1.69 ng/ml) for HC, MS 
relapse, and MS remission, respectively (Figures 1C,D). Serum 
samples were also tested for the presence of TLR2 stimulants, 
but these were below the limit of detection by the HEK293-TLR2 
transfection assay (data not shown).
Similar to sTLR2, we found significantly higher levels of serum 
CRP during MS relapse compared to HC, although, there was 
no significant difference between paired relapse and remission 
samples (Figures  1E,F). This raised the possibility that sTLR2 
may be increased in relation to the acute phase reaction (APR). 
FigUre 2 | Comparison of serum soluble TLR2 (sTLR2) levels in the discovery cohort, validation cohort, and pooled data measured by enzyme-linked 
immunosorbent assay and analysis of pooled data. The data are presented as mean ± SD. (a) sTLR2 measured in the serum samples from RRMS patients and HC 
in the discovery cohort (n = 21 RRMS, 24 HC). Mann–Whitney test showed significantly higher sTLR2 values in the RRMS patients (P < 0.0001). (B) sTLR2 levels 
measured in the serum samples from RRMS patients and HC in the validation cohort (n = 20 RRMS, 20 HC). Mann–Whitney test showed no significant difference 
between RRMS patients and HC (P = 0.6061). (c) sTLR2 levels in the serum samples were pooled together from two cohorts and compared between patients and 
HC (n = 41 RRMS, 44 HC). Mann–Whitney test showed highly significant difference between RRMS patients and HC (P = 0.0006).
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However, there was no significant correlation between serum 
levels of CRP and sTLR2 or sTLR4, and an in vitro model of the 
APR (interleukin-1β treated hepatocarcinoma cell line cells), 
revealed that sTLR2 is not released by stimulated hepatocytes 
(data not shown). Together, these findings suggest that the 
observed increase in serum sTLR2 in MS patients is likely not 
directly caused by the APR.
serum sTlr2 is not significantly elevated 
in Validation cohort but significant in the 
Pooled Data
To validate the sTLR2 elevation in the serum of RRMS patients, 
we performed ELISA tests in the sera of an independent cohort 
of patient and HC from a different population (Piedmont, North-
Western Italy). There was a similar upward trend of mean sTLR2 
levels in the serum samples of RRMS patients (0.907  ng/ml) 
compared to HC (0.836 ng/ml) and the values were almost in the 
same concentration range as in the discovery data set although it 
did not reach statistical significance (P = 0.6061) (Figures 2A,B). 
We, therefore, pooled the data from our original discovery 
cohort and the validation cohort to see the overall trend. In the 
pooled data, sTLR2 levels were 0.888 and 0.696  ng/ml in the 
RRMS (n = 41) and HC (n = 44), respectively, and the analysis 
retained the original significance (P =  0.0006, Mann–Whitney 
test) (Figure 2C). We also measured the levels of sTLR4 in the 
serum samples from the validation cohort and the trend was the 
same as observed in our discovery cohort, with values that were 
very low or below the detection limit (data not shown).
Tlr2 surface expression on cD4+ T cells 
Does not Differ between Ms relapse  
and remission, but is reduced  
by calpain Treatment
As we reported recently that Tregs from RRMS patients are 
more susceptible to TLR2-stimulation than those of HC (19), we 
explored whether CD4+ T cells may have potential to contribute 
to the circulating pool of sTLR2. The percentage of CD4+ T cells 
surface expression of TLR2 was not significantly different between 
relapse and remission (Figures 3A–C). However, previous studies 
have shown that extracellular calpain, a cysteine protease released 
by T  lymphocytes, has the ability to cleave TLR2, leading to 
increased levels of sTLR2 in the extracellular environment both 
in mice and humans (26). Treatment with exogenous calpain 
led to a non-significant reduction in TLR2 surface expression 
on CD4+ T cells (data not shown). However, we were unable to 
confirm this trend by ELISA, as sTLR2 levels were below the limit 
of detection in the supernatants of T cells cultured in the presence 
of calpain (data not shown).
Tlr2 stimulant activity but not sTlr2  
or sTlr4 are significantly raised  
in the Urine of Ms Patients compared  
to controls
Soluble TLR2 may be released in response to excessive TLR2-
stimulation (25) and so we sought evidence of potential sources 
of TLR2-stimulants that may be of relevance to MS. As UTI is a 
common complication of MS (33), we used urine dipstick tests to 
seek evidence of UTI in MS patients. Although levels of protein 
and erythrocytes were significantly increased in urine of MS 
patients compared to HC (Table 2), there were no significant dif-
ferences in overall positivity for markers of infection between the 
groups, using this method. To gain further insight into whether 
MS patients may be exposed to increased TLR2-stimulants 
as a result of subclinical UTI not detectable by dipstick, we 
used a HEK293-TLR2 transfection assay calibrated with the 
synthetic ligand Pam3CSK4 to quantify the biological activities 
of TLR2-stimulants present in urine of HC and MS patients, as 
described previously (28). These measurements revealed that 
TLR2-stimulant activities were far greater in urine samples of MS 
patients compared to HC (1.72, 126.2, and 55.5 ng/ml), relative 
to Pam3CSK4-equivalent activity, for HC, MS relapse, and MS 
remission, respectively [P = 0.0004, P = 0.0020 (Figures 4A,B)].
TaBle 2 | Results from urine dipstick tests.
group leu nit Prot eryt any (+ve)
Relapse (n = 19) 26% 21% 26% 26% 53%
Remission (n = 22) 14% 9% 23% 32% 41%
HC (n = 13) 8% 15% 0% 0% 23%
P value (Chi2 test HC 
vs all MS samples)
0.319 0.947 0.049 0.027 0.137
Leu, leukocytes; Nit, nitrite; Prot, protein; Eryt, erythrocytes.
FigUre 3 | TLR2 surface expression in relapsing-remitting MS patients and effect of Calpain on TLR2 expression. (a,B) Representative flow cytometry dot plots 
showing percentage of CD4+ TLR2+ cells for the same patient during relapse and remission. Cells were gated on lymphocytes then live cells and then double gated 
for CD4 and TLR2. (c) Graphs showing the percentage of CD4+ TLR2+ lymphocytes comparing between relapse and remission in paired samples (n = 14). Data 
are presented as mean ± SD. Wilcoxon matched-pairs signed rank test gave the P value of 0.1937 showing no significant difference in TLR2 surface expression 
between relapse and remission.
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Soluble TLR2 and sTLR4 levels were also measured in urine 
samples of HC and MS patients. Urinary sTLR2 levels were 
higher than measured in serum, but unlike serum sTLR2 levels, 
there were no statistically significant differences between HC and 
MS groups (Figures 4C,D). sTLR4 levels were below the limit of 
detection in most urine samples and the mean values were also 
not significantly different between the groups (Figures 4E,F).
Diverse UTi-related Bacteria stimulate 
Tlr2-signaling
These findings suggested potential involvement of UTI-related 
bacteria in the stimulation of TLR2 in MS patients. To explore 
which types of bacteria may contribute to such activity, a panel 
of representative UTI-relevant bacteria was tested for their ability 
to trigger TLR2-signaling using the HEK293-TLR2 transfection 
system. All the Gram-negative organisms tested (Esche richia coli, 
Klebsiella pneumoniae, Pseudomonas aeruginosa, and Proteus 
vulgaris) were potent stimulators of TLR2-signaling (Figure 5A). 
However, while two of the Gram-positive organisms stimulated 
strong TLR2-signaling (Staphylococcus aureus and Staphylococcus 
epidermidis), two induced little or no TLR2-signaling (Enter­
ococcus faecalis and Streptococcus pyogenes). As infection with 
the gastric pathogen H. pylori has also been associated with MS 
(34), the TLR2-stimulating capacity of H. pylori lysate was 
assessed, confirming that this organism also contains abundant 
TLR2-stimulants (Figure 5B). Thus, diverse bacteria responsible 
for infections which may be relevant to MS, of both Gram-
positive and Gram-negative origin, are potent triggers of TLR2 
signaling.
DiscUssiOn
Increasing evidence supports a potential involvement of TLR2 
in the development of MS. TLR2 is upregulated on PBMCs, 
Tregs, cerebrospinal fluid mononuclear cells, and in demyelinat-
ing lesions of MS patients [reviewed in Ref. (4)]. Experimental 
administration of defined bacterial ligands of TLR2, or the Gram-
positive bacterium Streptococcus pneumoniae, increases clinical 
score in the murine EAE model of MS in a manner dependent 
on TLR2 (35, 36). Although experiments using mice globally 
deficient in TLR2 have yielded mixed results (4), adoptive trans-
fer of TLR2-deficient T cells was shown to result in significantly 
reduced pathology in the passive EAE model, suggesting a key 
involvement of TLR2-signaling in T cells (37). Accordingly, we 
have shown that TLR2 stimulation of human Tregs impairs their 
suppressive function, and drives their differentiation toward an 
inflammatory Th17-like phenotype, particularly in cells from 
RRMS patients (18).
In this study, we sought evidence of TLR2 activity in MS 
clinical samples. We report, for the first time, that serum sTLR2 
levels are significantly elevated in MS patients compared to 
match HC (Figure  1A). This is consistent with observations 
of increased serum sTLR2 in a number of other inflammatory 
diseases and disease models, including severe bacterial infection 
(38), experimental human endotoxemia (32), and the autoim-
mune disease systemic lupus erythematosus, where it serves as 
a biomarker of disease activity (29). Notably, sTLR2 can act as a 
FigUre 4 | Level of soluble TLR2 (sTLR2), sTLR4, and TLR2 stimulants in the urine of relapsing-remitting (RR) MS (RRMS) patients compared with HC. sTLR2 and 
sTLR4 were measured by enzyme-linked immunosorbent assay (ELISA) and urinary TLR2 stimulants were measured in human embryonic kidney (HEK)-293-TLR2 
transfection system. (a) TLR2 stimulants in the urine of RRMS patients were measured in HEK-293-TLR2 transfectant system during relapse (n = 18) and compared 
with HC (n = 11). Mann–Whitney test showed a significantly higher TLR2 stimulants in the urine of MS patients during relapse (P = 0.0004) compared with HC. 
Significantly higher urinary TLR2 stimulants were also observed during remission (n = 13) compared to HC (P = 0.0020) (not shown). (B) Wilcoxon matched-pairs 
signed rank test between relapse and remission also showed no significant difference (n = 13, P = 0.0803). The values are expressed as ng/ml of the bacterial 
lipopeptide equivalent and the data are presented as mean ± SD. The data in Figure 3 (a,B) are log transformed from original values. (c) sTLR2 measured in the 
urine samples from RRMS patients during relapse (n = 19) and HC (n = 13). The data are presented as mean ± SD. Mann–Whitney test showed no significant 
differences between HC vs relapse (P = 0.6498). HC vs remission (n = 20) also showed no significant difference (P = 0.2383) (not shown). (D) Wilcoxon matched-
pairs signed rank test showed no significance between relapse and remission (P = 0.3054). (e) sTLR4 measured in the urine samples from RRMS patients during 
relapse (n = 17) and HC (n = 10). The data are presented as mean ± SD. Mann–Whitney test showed no significant differences between HC vs relapse 
(P = 0.1406). HC vs remission (n = 14) also showed no significant difference (P = 0.9290) (not shown). (F) Wilcoxon matched-pairs signed rank test showed no 
significance between relapse and remission (n = 14, P = 0.1875). *** P < 0.001. ns, not significant.
7
Hossain et al. sTLR2 in MS: A Potential Disease Biomarker
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 457
decoy microbial receptor since it retains the capacity to bind with 
the PAMPs as well as TLR2 coreceptor CD14, thereby preventing 
surface TLR2 to bind with CD14 and PAMPs. The net effect is to 
reduce TLR2 activation (22). This has relevance for MS relapses, 
during which reduced TLR2 signaling might potentially attenuate 
inflammatory activity and clinical severity. When repeating sTLR 
measurement in an independent validation cohort, we found a 
trend toward higher sTLR2 levels in the RRMS patients compared 
to HC, with values in a similar concentration range as observed in 
our discovery dataset (Figures 2A,B). When we pooled the data 
from two cohorts, however, statistical differences between the 
RRMS (n = 41) and HC (n = 44) groups were highly significant 
(Figure 2C). The larger number of subjects studied in the pooled 
dataset gives us more assurance on the validity of the observation. 
To our knowledge, no previous study has reported sTLR2 levels in 
MS patients. We further analyzed the results to see whether treat-
ments with DMTs had any influence on the serum sTLR2 levels 
and none was found either in the discovery cohort (P = 0.5201) 
or in the pooled data (P = 0.7587; all patients in the validation 
data were untreated).
The dominant cell-type responsible for increased sTLR2 
release in MS remains to be clearly established. There was 
significant elevation in the levels of CRP between relapsing MS 
patients and HC indicative of chronic low-grade inflammation 
(Figure 1E) although no correlation between sTLR2 and hsCRP 
were observed which is consistent with a recent finding in 
diabetes (39). The lack of correlation with CRP, and its absence 
from stimulated hepatocyte cultures, suggests that it is likely not 
released by hepatocytes as part of the APR. We suspected that it 
may be released from CD4+ T cells, which express higher TLR2 
in MS patients (30). However, sTLR2 released from CD4+ T cells 
treated with calpain (25) was not detectable, perhaps due calpain 
cleavage of epitopes required for binding by the antibodies used 
in the ELISA assay.
Although sTLR2 was readily detected in urine, urinary epithe-
lial cells are also not likely the dominant source of serum sTLR2 in 
MS, since we saw no significant correlation between urinary and 
serum sTLR2 levels. There is recent evidence that nanovesicular 
exosomes derived from TLR-stimulated cells can communicate 
to other cells, reproduce a TLR-mediated response to infection, 
FigUre 5 | Stimulation of TLR2 signaling by urinary tract infections relevant heat-killed bacteria and H. pylori lysate. Pam3Cys (100 ng/ml) was used as the 
standard agonist for TLR2 and DMEM medium with 1% serum (D1) was used as control. H. pylori lysate also triggered robust TLR2-signaling in all four dilutions 
used, but one-way ANOVA did not reveal any dose effect (P = 0.0930). The results are expressed as NF-kB fold induction. (a) Effects of selected heat-killed 
bacteria on TLR2-signaling in human embryonic kidney (HEK)-293-TLR2 transfectants. The bacteria tested includes four Gram-positive (E. faecalis, S. aureus,  
S. epidermidis, and S. pyogenes) and four Gram-negative (E. coli, K. pneumoniae, P. aeruginosa, and P. vulgaris) species. Two different dilutions (106 bacteria/ml  
and 105 bacteria/ml) prepared in D1 was tested. The bars represent the results of three independent experiments expressed as mean ± SD. (B) Effect of H. pylori 
lysate on TLR2 signaling in HEK-293-TLR2 transfectants. Four different dilutions of the samples (1:10, 1:100, 1:1 K, 1:10 K) were tested. The bars represent the 
results of three independent experiments expressed as mean ± SEM. One-way ANOVA did not reveal any dose effect (P = 0.0930).
8
Hossain et al. sTLR2 in MS: A Potential Disease Biomarker
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 457
and modulate inflammation by preventing further binding of the 
TLR ligands (40). Further studies should investigate the content 
of exosomes derived from TLR2-stimulated cells as a potential 
source of sTLR2 and its possible effect on TLR2 signaling. More 
work will be required to establish which cell type is the dominant 
source of elevated sTLR2 in MS.
As sTLR2 is released in response to TLR2 overstimulation 
to downregulate inflammation (25, 32), we sought potential 
sources of TLR2-stimulants in MS clinical samples. UTIs are 
frequent in MS (33, 41), and there is evidence that disease exac-
erbations may be linked to recent UTI, particularly by Gram-
negative bacteria (42, 43). Dipstick tests revealed no significant 
differences in frequency of indicators of infection between 
relapse and remission urine samples of our cohort. However, 
since dipstick tests have low sensitivity and lack reliability in 
diagnosing UTI (44, 45), we sought evidence of subclinical UTI 
using the more sensitive HEK-293-TLR2 transfection system, 
which can detect as few as 104 bacterial cells/ml independently 
of bacterial viability (28).
This assay revealed that urine samples from MS patients in 
both relapse and remission contained a significantly greater 
content (~32–72 fold) of TLR2 stimulants than urine samples 
from HC (Figure 4A). Thus, subclinical UTI, at levels undetect-
able by dipstick test, may be more common in MS patients than 
previously thought (15, 44). Soluble TLRs, including sTLR2, are 
negative regulators of TLR signaling and function as a feedback 
mechanism to inhibit excessive TLR activation (20). In the con-
text of this study, we hypothesized that overactivation of TLR2 by 
UTI-related organisms could induce intrinsic cellular processes 
mediated by proteolytic enzymes to cleave surface TLR2, release 
sTLR2, and downregulate TLR2 signaling. Although Gram-
negative bacteria are commonly thought to be sensed principally 
via TLR4, we found that common UTI-relevant Gram-negative 
bacteria are also potent stimulators of TLR2 (Figure  5A). 
H. pylori lysate also triggered robust TLR2-signaling at all four 
dilutions tested (Figure 5B).
As infection with this organism is less commonly observed 
in MS patients, we and others have suggested that it may have 
protective properties against MS (34, 46). If this is the case, it is 
possible that the organism’s capacity to trigger TLR2-signaling 
is countered by the numerous modifiers of innate immune and 
T-lymphocyte function, particularly those resulting in increased 
Treg and reduced Th17 function, which H. pylori is established 
to secrete (47).
In conclusion, we report that two different markers of 
TLR2-activity—urinary TLR2-stimulants, and serum sTLR2 
levels—are significantly elevated in MS patients compared to 
HC regardless of the treatment status. Although we saw no 
significant differences in these markers between relapse and 
remission samples in this study, this could be due to limited 
study power. Therefore, larger studies will be required to 
determine whether subclinical UTI is related to relapse in MS, 
and whether increased serum sTLR2 level could be used as a 
diagnostic marker for inflammation or disease exacerbation 
in MS.
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